ALNY Alnylam Pharmaceuticals Inc

NASDAQ
$159.89

Alnylam Pharmaceuticals Inc (ALNY) is expected to report earnings on January 28, 2027, before the market open. The consensus earnings estimate is $1.68 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of -13.9% since its last earnings release on October 29, 2026.

Alnylam Pharmaceuticals Beat Consensus Estimates, Sees Revenue Below Estimates
Thursday, October 29, 2026 · 8:00 AM ET
Earnings Date
4th Quarter, Dec 2026
Jan 28
Thursday · 8:00 AM ET
Earnings Whisper
-
vs $1.68
Rev est $1.52B
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP $166.95

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About Alnylam Pharmaceuticals Inc

Alnylam Pharmaceuticals Inc is a biopharmaceutical company developing novel therapeutics based on RNA interference, or RNAi.

Sector

Healthcare

Industry

Biotechnology

Held By 6 ETFs, by dollar flow

Charts powered in part by Lightweight Charts™ by TradingView.